The New York Times reports on the Phase 1 clinical trial results of the new melanoma drug PLX4032. This drug specifically inhibits BRAF, a gene often mutated in advanced melanoma cancer. Read the full story here:
http://www.nytimes.com/2010/02/23/health/research/23trial.html?pagewanted=2&ref=health
No comments:
Post a Comment